Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CGON vs XNCR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

XNCR Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 5–5 Matrix Metrics)

XNCR Overall Winner 6-Pillar Tally: CGON 1 – 5 XNCR Matrix Metrics: CGON 5 – 5 XNCR

As of Nov 16, 2026, Xencor, Inc. (XNCR) is the stronger overall head-to-head candidate over CG Oncology, Inc. (CGON) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CGON carries a Unified Composite Score of 45.0/100 (HOLD) at $84.94 (N/M Forward P/E, -4293.5% operating margin), whereas XNCR carries 29.6/100 (SELL) at $35.61 (68.0x Forward P/E, -72.7% operating margin).

  • Composite vs. Pillar Nuance: While CGON currently prints a higher short-term Unified Composite Score (45.0/100 HOLD vs. XNCR 29.6/100 SELL), XNCR captures the overall institutional head-to-head verdict (5–5 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-72.7% vs. -4293.5% operating margin) and revenue trajectory (+454.9% vs. -3.7% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CGON vs XNCR
CGON NASDAQ
CG Oncology, Inc. Common stock
Biological Products, (No Disgnostic Substances)
$84.94
+14.16% 1D
Market Cap $6.3B
TTM Revenue $6.2M
Forward P/E N/M
Beta / 30D Vol 0.77β · 86% Vol
Unified Composite Score
45.0 / 100 HOLD
Tech 15.0 Fund 44.0 Flow 69.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 72
RSI-14: 71.7 · SMA20: $67.45 · SMA50: $68.25
XNCR NASDAQ Head-to-Head Winner
Xencor, Inc.
Pharmaceutical Preparations
$35.61
-3.99% 1D
Market Cap $2.9B
TTM Revenue $200M
Forward P/E 68.0x
Beta / 30D Vol 1.21β · 87% Vol
Unified Composite Score
29.6 / 100 SELL
Tech 50.0 Fund 32.0 Flow 66.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (9.7% over 20 days), RSI 62
RSI-14: 62.5 · SMA20: $32.16 · SMA50: $27.52

6-Pillar Scorecard Institutional Category Breakdown (CGON 1 – 5 XNCR)

Columns: Metric · CGON · XNCR
1. Valuation Multiples XNCR
Forward P/E N/M 68.0x
Trailing P/E N/M 68.0x
PEG Ratio N/M N/M
EV / Revenue N/M 14.8x
2. Growth & Scale XNCR
Revenue Growth (YoY) -3.7% +454.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $6.2M $200M
Market Cap $6.3B $2.9B
3. Profitability & Quality XNCR
Gross Margin N/A -42.5%
Operating Margin -4293.5% -72.7%
Net Profit Margin 0.0% -58.8%
Return on Equity (ROE) -28.3% -19.9%
4. Balance Sheet & Cash Flow XNCR
Cash Generation (TTM) -$189M -$176M
Cash Flow Margin N/A -88.0%
Net Cash / Leverage $19M Net Cash $101M Net Debt (0.29x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CGON
Options Structure Phase CONSOLIDATION BREAKOUT
Current IV / %ile 238.6% (85th %ile) 79.0% (10th %ile)
Put/Call OI Skew 0.35x (Call-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Neutral ACCUMULATION · Markup
6. R&D & Supply-Chain Moat XNCR
OpEx & R&D Intensity N/A 30.2% of Rev ($61M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CGON (5) vs XNCR (5)
Institutional Metric CGON XNCR Criterion Row Edge
Market Capitalization
Scale
$6.3B $2.9B Larger Scale CGON
Trailing P/E Ratio
Valuation
N/M 68.0x Lower Multiple XNCR
Forward P/E Ratio
Valuation
N/M 68.0x Lower Multiple XNCR
Revenue Growth (YoY)
Growth
-3.7% +454.9% Higher Growth XNCR
Operating Margin (TTM)
Profitability
-4293.5% -72.7% Higher Margin XNCR
Net Profit Margin
Profitability
0.0% -58.8% Higher Margin CGON
Return on Equity (ROE)
Capital Efficiency
-28.3% -19.9% Higher ROE XNCR
52-Week Range Position
Momentum
84% ($37–$94) 84% ($10–$41) Stronger Trend CGON
Beta / 30D Volatility
Risk Regime
0.77β · 86% Vol 1.21β · 87% Vol Lower Realized Risk CGON
Unified Institutional Score
Composite Signal
45.0 / 100 (HOLD) 29.6 / 100 (SELL) Higher Composite CGON
Trailing 12M Revenue (USD)
Operating Scale
$6.2M $200M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A -42.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 14.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$189M ($19M Net Cash) -$176M ($101M Net Debt (0.29x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon XNCR +13.93 pp
CGON: +41.91% · XNCR: +55.84%
3M Horizon XNCR +28.81 pp
CGON: +11.33% · XNCR: +40.14%
6M Horizon XNCR +187.0 pp
CGON: +34.97% · XNCR: +221.97%
1Y Horizon XNCR +29.61 pp
CGON: +124.93% · XNCR: +154.54%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CGON Revenue XNCR Revenue CGON Op. Margin XNCR Op. Margin Margin Leader
FY2018 N/A $40M N/A -195.5% XNCR
FY2019 N/A $160M N/A 8.8% XNCR
FY2020 N/A $120M N/A -62.6% XNCR
FY2021 N/A $280M N/A 15.9% XNCR
FY2022 N/A $160M N/A -50.1% XNCR
FY2023 $0M $170M -27180.9% -75.8% XNCR
FY2024 $0M $110M -10067.3% -161.5% XNCR
FY2025 $0M $130M -4722.1% -141.4% XNCR

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CGON CONSOLIDATION
62d in phase · OBV ACCUMULATION
Current IV 238.6%
IV Percentile 85th %ile
Put/Call OI Skew 0.35x (Call-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact CGON Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
XNCR BREAKOUT
58d in phase · OBV ACCUMULATION
Current IV 79.0%
IV Percentile 10th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow ACCUMULATION
Exact XNCR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CGON Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $6.3B market capitalization and -4293.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
XNCR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.9B market capitalization and -72.7% operating margin.
OpEx & R&D Reinvestment 30.2% of Rev ($61M)
90D Engineering Disclosures 0 Published

Investor FAQ CGON vs XNCR Key Questions & Quantitative Answers

As of Nov 16, 2026, Xencor, Inc. (XNCR) is the stronger overall head-to-head candidate over CG Oncology, Inc. (CGON) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CGON carries a Unified Composite Score of 45.0/100 (HOLD) at $84.94 (N/M Forward P/E, -4293.5% operating margin), whereas XNCR carries 29.6/100 (SELL) at $35.61 (68.0x Forward P/E, -72.7% operating margin). Composite vs. Pillar Nuance: While CGON currently prints a higher short-term Unified Composite Score (45.0/100 HOLD vs. XNCR 29.6/100 SELL), XNCR captures the overall institutional head-to-head verdict (5–5 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-72.7% vs. -4293.5% operating margin) and revenue trajectory (+454.9% vs. -3.7% YoY).

XNCR leads the Growth & Scale pillar: CGON posts -3.7% YoY revenue growth and +0.0% YoY earnings growth on $6.2M TTM revenue (N/A gross margin, -4293.5% operating margin), compared with XNCR at +454.9% YoY revenue growth and +0.0% YoY earnings growth on $200M TTM revenue (-42.5% gross margin, -72.7% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), CGON cumulative revenue shifted N/A while XNCR shifted +225.0%. In operating R&D and SG&A reinvestment, CGON deploys N/A (0 90-day corporate R&D disclosures) versus 30.2% of Rev ($61M) (0 disclosures) for XNCR.

XNCR screens cheaper on headline valuation multiples. CGON trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas XNCR trades at 68.0x Forward P/E, 68.0x Trailing P/E, N/M PEG, and 14.8x EV/Revenue (-88.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CGON (-28.3% ROE) versus XNCR (-19.9% ROE) capital efficiency.

In options market volatility and institutional positioning, CGON carries 238.6% implied volatility (85th %ile, Extreme (>80th %ile)), a 0.35x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.77β · 86% Vol realized risk). By comparison, XNCR carries 79.0% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.21β · 87% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.